LC-TDS Platform

About Cutanos

Cutanos is a private, preclinical-stage biotech founded in 2020 in Vienna, Austria, focused on a first-of-its-kind targeted delivery platform for mRNA therapeutics. Its proprietary Langerhans Cell Targeted Delivery System (LC-TDS) utilizes a ligand to specifically target a key subset of skin-resident dendritic cells, aiming to enhance vaccine efficacy while reducing doses and side effects. The company is leveraging its modular platform to develop next-generation vaccines and is supported by Austrian public funding agencies and experienced biotech advisors. Cutanos operates as a platform company, positioning its technology for applications in infectious diseases, oncology, and potentially autoimmune disorders.

Therapeutic Areas